Bausch Health Joseph Papa, Bausch Health Joe Papa

Mr. Papa has been serving on the Board of Directors for Bausch Health Companies Inc. since May 2016 as Chairman and Chief Executive Officer. He has more than 35 years of experience in the pharmaceutical, health care and specialty pharmaceutical industries, including 20 years of branded prescription drug experience.

Prior to Bausch Health, he was the Chief Executive Officer of the Perrigo Company from 2006 to April 2016. Before that, Papa served as Chairman and Chief Executive Officer of Cardinal Health’s Pharmaceutical Technologies and Services business unit (2004 – 2006). He was President and Chief Operating Officer for Watson Pharmaceuticals (2001 – 2004), President of Global Country Operations for Pharmacia’s North American business (2000 – 2001) and President of Searle’s U.S. Operations (1997 – 2000). Prior to Searle/Pharmacia, Papa served in a variety of general management, sales, marketing and R&D positions during his 15-year career at Novartis Pharmaceuticals Corporation (1983 – 1997). During his career, he led teams that successfully launched several blockbuster pharmaceutical products, including Lotrel, Diovan and Celebrex, and he is the patent holder for a cardiovascular combination treatment containing Amlodipine and Benazepril.

In October 2014, Harvard Business Review ranked Papa 47th on its “2014 Best Performing CEOs in the World.” He was also recognized on Israel-based Calcalist Magazine’s “Best Chief Executive Officer for the Year” list for 2013 and 2014. Additionally, Papa was named one of the World’s Best CEOs by Barron’s magazine in 2012, which noted Perrigo “generated one of the best shareholder returns in the S&P 500 in the past five years.”

He is a past member of the UConn Foundation Board of Directors and the Smith & Nephew Board of Directors, where he served as Chairman of the Remuneration Committee.

Papa holds a B.S. in pharmacy from the University of Connecticut and an MBA from Northwestern University’s Kellogg Graduate School of Management. In 2012, he received an Honorary Doctor of Science degree from the University of Connecticut’s School of Pharmacy.

Bausch Health Christina Ackermann

Christina Ackermann joined the company as Executive Vice President, General Counsel, in August 2016. In this role, she is responsible for Bausch Health’s worldwide legal affairs, compliance, global security and enterprise risk management. In June 2020, she was named Head of Commercial Operations. Prior to Bausch Health, Ackermann was part of the Novartis group of companies for 14 years, most recently serving as Senior Vice President, General Counsel for Alcon, where she was responsible for the for the legal, intellectual property and compliance functions. Previously, she served as Global Head, Legal and General Counsel at Sandoz, the generics division of Novartis, from 2007 to 2012. She joined Novartis Pharma in 2002 as Head, Legal Technical Operations and Ophthalmics, and assumed the role of Head Legal General Medicine in July 2005. Before Novartis, Ackermann served in Associate General Counsel roles with Bristol Myers Squibb and DuPont Pharmaceuticals, as well as in private practice, where she focused on securities, and mergers & acquisitions. Ackermann attended York University, Toronto, Canada, for her undergraduate studies, focusing initially on fine arts and later moving into mathematics and political sciences. Ackermann also attended Queen's University, Kingston, Canada, where she obtained her LL.B., and King’s College at the University of London, UK, where she obtained a Post Graduate Diploma in EC Competition Law.

Bausch Health Thomas Appio
Bausch Health Paul Herendeen

Paul Herendeen joined the company in August 2016. Previously, he served as Executive Vice President and Chief Financial Officer of Zoetis Inc., the global animal health company, for two years. From 2005 to 2013 and from 1998 to 2001, Herendeen served as CFO at Warner Chilcott, a specialty pharmaceuticals company. He rejoined Warner Chilcott after four years as Executive Vice President and CFO of MedPointe, a privately held health care company, where he served as CFO from 2001 until 2005. Prior to that, Herendeen spent nine years as a principal investor at Dominion Income Management and Cornerstone Partners, where he worked on investments as well as mergers & acquisitions for the firms and their portfolio companies. He spent the early part of his career in banking and public accounting, holding various positions with the investment banking group of Oppenheimer & Company, the capital markets group of Continental Bank Corporation and as a senior auditor with Arthur Andersen & Company. Herendeen earned a Master of Business Administration (MBA) from the University of Virginia's Darden School of Business, and holds a bachelor's degree in Business Administration from Boston College.

Bausch Health Bill Humphries, Bausch Health William Humphries
Bausch Health Robert Spurr
Bausch Health Dennis Asharin
Bausch Health Joseph Gordon
Bausch Health Jeff Hartness
Bausch Health Scott Hirsch

Scott Hirsch joined the company in August 2016 from Citadel Investment Group, where he oversaw equity investments and risk management decisions within the Health Care sector at Surveyor Capital. Earlier in his career, he was in the investment banking group of Credit Suisse as the Lead Equity Research Analyst covering Specialty Pharmaceuticals and Generics.

Bausch Health Barbara Purcell
Bausch Health Tage Ramakrishna

Dr. Tage Ramakrishna has been with the company since 2011 and has more than 15 years of experience in the pharmaceutical industry, including positions at Progenics Pharmaceuticals, Nycomed in Zurich Switzerland, and Insmed Pharmaceuticals.

Bausch Health Kelly Webber
Bausch Health Louis Yu

Louis Yu joined the company in October 2016 with more than 30 years of leadership experience in the Quality and R&D functions of generic and branded pharmaceutical companies. He was Executive Vice President, Global Quality & Compliance at Perrigo Company from 2006 to 2016.